Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Immuntherapie-Basisnorm für die Erstlinie und lokale abblative Behandlungen für nicht-kleinzellige Lungenkrebspatienten oligometastatisch. (OliGRAIL)

4. November 2026 aktualisiert von: Gustave Roussy, Cancer Campus, Grand Paris

First-Line-Immuntherapie-basierte Versorgung und lokale abblative Behandlungen für oligometastatische nicht-kleinzellige Lungenkrebspatienten: eine randomisierte, multizentrische, offene Phase-III-Studie

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

124

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Caen, Frankreich, 14076
      • Lille, Frankreich, 59000
        • Rekrutierung
        • Centre Oscar Lambret
        • Kontakt:
      • Lyon, Frankreich, 69000
        • Rekrutierung
        • Hospices Civils de Lyon (HCL)
        • Kontakt:
      • Nice, Frankreich, 06001
        • Rekrutierung
        • CHU Nice
        • Kontakt:
      • Nîmes, Frankreich, 30029
        • Rekrutierung
        • Institut de Cancérologie du Gard
        • Kontakt:
      • Paris, Frankreich, 75014
        • Rekrutierung
        • Hôpital Paris Saint- Joseph
        • Kontakt:
      • Tarbes, Frankreich, 65000
        • Rekrutierung
        • Polyclinique Ormeau
        • Kontakt:
    • Hauts-de-France
      • Creil, Hauts-de-France, Frankreich, 60100
        • Rekrutierung
        • Institut de Radiothérapie du Sud de l'Oise
        • Kontakt:
        • Hauptermittler:
          • Andres HUERTAS, MD
    • Provence-Alpes-Côte d'Azur Region
      • Avignon, Provence-Alpes-Côte d'Azur Region, Frankreich, 84000
        • Rekrutierung
        • Centre Sainte-Catherine
        • Kontakt:
        • Hauptermittler:
          • Nicolas POUREL, MD
    • Île-de-France Region
      • Saint-Cloud, Île-de-France Region, Frankreich, 92210
        • Rekrutierung
        • Institut Curie
        • Kontakt:
      • Villejuif, Île-de-France Region, Frankreich, 94805
        • Rekrutierung
        • Gustave Roussy
        • Hauptermittler:
          • Antonin LÉVY, MD
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Histologically proven advanced synchronous oligometastatic stage IV NSCLC.
  • NSCLC patients eligible first line immunotherapy-based SoC according to the European Marketing Authorization.
  • PDL1 status available.
  • Metastases eligible to RLT according to the local multidisciplinary board (MTB): ≤5cm each in CT scan, excluding primary tumour.
  • Maximum 5 metastases in 3 organs (EORTC criteria), according to brain MRI and FDG-PET.
  • Symptomatic lesions requiring urgent palliative radiation, is permitted prior to randomization. These treated lesions should be counted towards the total number of metastases at the time of enrolment.
  • Clinically required brain metastases (BM) ablation (surgery and/or SBRT) is permitted and BM count within the total number of 5 lesions. The patient would then be randomized to treatment of their extracranial disease.
  • Acceptable organ function for RLT.
  • ECOG performance status (PS) 0-1.
  • Measurable lesions according to RECIST V1.1 on standard imaging.
  • Patient aged 18 or more.
  • Woman of childbearing potential must agree to use adequate contraception (implant type, vaginal ring, contraceptive pill, contraceptive patch, Intrauterine Device (IUD), etc.) for the duration of study participation and up to 6 months after completing treatment/therapy, in addition, male partners use a condom during this same period. Male patients must agree to use condom for the duration of study participation and up to 6 months after completing treatment/therapy.
  • Patients affiliated to the social security system.
  • Patient should understand, sign, and date the informed consent form written in French prior to any protocol-specific procedures performed.
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion Criteria:

  • Non-squamous NSCLC with targetable tumour mutations and approved first line targeted therapy (such as EGFR, ALK and ROS1).
  • Metastases not eligible to RLT: e.g. brainstem or diffuse serosal metastases (meningeal, pericardial, pleural, peritoneal, mesenteric) or that invades the gastrointestinal tract.
  • Brain metastases only, without extra-cerebral metastases.
  • Uncontrolled severe comorbidity, symptomatic interstitial lung disease or active infection.
  • Prior therapy with T-cell costimulation or immune checkpoint-targeted agents within 1 year.
  • Uncontrolled concomitant (<1-year) malignancy except adequately treated basal or squamous cell carcinoma of the skin, or in-situ carcinoma of any organ or in-situ melanoma of the skin.
  • Persons deprived of liberty by judicial or administrative decision.
  • Persons subject to a legal protection measure (guardianship, curatorship, safeguard of justice).
  • Persons not affiliated to a social security system or equivalent.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Experimental arm: RLT + SoC-based immunotherapy (+/- chemotherapy)

RLT of all metastatic sites should be administered within 3 months after randomization and should not delay SoC-based immunotherapy administration.

RLT of all metastatic sites. The possible RLT options will be SBRT, interventional radiology and/or minimally invasive surgery. Depending on the metastatic site, access and patient condition, the best RLT should be initially discussed in a case-to-case basis at the local multidisciplinary board (MTB).

The primary tumour and initially invaded lymph nodes should be treated during the maintenance phase. Curative-intent approach modalities (e.g. hypofractionated intensity-modulated thoracic radiation therapy or surgery) should be discussed at the local MTB.

Andere Namen:
  • SBRT
  • Interventionellen Radiologie
  • Minimal-invasive Chirurgie

Current French SoC will be used. Main SoC-based immunotherapy includes:

  • Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.
  • Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).

Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.

Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...).

Aktiver Komparator: Control arm: SoC-based immunotherapy (+/- chemotherapy)

SoC-based immunotherapy (+/- chemotherapy) will be administered every 3 weeks

Current French SoC will be used. Main SoC-based immunotherapy includes:

  • Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.
  • Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).

Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.

Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...).

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall Survival (OS).
Zeitfenster: From date of randomization up to two years after the randomization of the last patient or documented death.

Time from randomization to the date of documented death from any cause or last follow-up.

From date of randomization up to two years after the randomization of the last patient or documented death.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression-free survival (PFS) according to RECIST 1.1.
Zeitfenster: From date of randomization up to two years after the randomization of the last patient or documented death.

Time between the randomization date and the date of observation of a progression of the disease according to RECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up.

From date of randomization up to two years after the randomization of the last patient or documented death.
immune Progression-free survival (iPFS) according to iRECIST.
Zeitfenster: From date of randomization up to two years after the randomization of the last patient or documented death.

Time between the randomization date and the date of observation of an progression of the disease according to iRECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up.

From date of randomization up to two years after the randomization of the last patient or documented death.
Number of side effects measured by CTCAE V.5.
Zeitfenster: From date of randomization up to two years after the randomization of the last patient or documented death.

Acute/ late adverse events graded by CTCAE v5 (toxic death and serious adverse events) and their imputability to treatment.

From date of randomization up to two years after the randomization of the last patient or documented death.
EORTC Quality of Life Questionnaire-C30 (EORTC QLQ-C30).
Zeitfenster: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

The EORTC Quality of Life Questionnaire-C30 (EORTC QLQ-C30) contains 30 questions and assesses the quality of life of oncological patients multidimensionally over 10 subscales. All sub-scales and the 6 individual items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life. In the symptom subscale, however, a higher score represents a higher level of symptoms or problems.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
EORTC Quality of Life Questionnaire Lung Cancer-specific-13 (QLQ-LC-13).
Zeitfenster: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

EORTC Quality of Life Questionnaire Lung Cancer-specific-13 (QLQ-LC-13) is a specific companion module used in conjunction with the EORTC QLQ-C30 and specifically developed for patients with Lung Cancer, and reliable in LC specific Qol assessment. The EORTC QLQ-LC13 comprises 13 item that measure lung cancer-related symptoms. Each items use the same 1-to-4 verbal response scale as the QLQ-C30 items, and domain scores are also transformed to a 0-to-100 metric. A higher score represents better function and a higher quality of life.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
EuroQol-5D-5L Questionnaire (EQ-5D-5L).
Zeitfenster: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

The EuroQol-5D-5L Questionnaire (EQ-5D-5L) descriptive system of 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Index scores range from -0.59 to 1; 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0. Used alongside the EQ-5D, the EQ visual analog scale (VAS) is a 20 cm VAS "assessing your own health today" with endpoints labeled "Best imaginable health state" (100) and "Worst imaginable health state" (0).

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
Clearance of circulating tumour DNA (ctDNA).
Zeitfenster: At the randomization, then Week 6 and Month 4 after randomization.

ctDNA assessed in plasma.

At the randomization, then Week 6 and Month 4 after randomization.
Economic evaluation.
Zeitfenster: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

Incremental cost per Quality-adjusted life year (QALY based on EQ-5D-5L measures), incremental net monetary benefit. Assess the cost-utility (cost per QALY) of RLT + immunotherapy-based SoC compared to immunotherapy-based SoC alone.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. September 2025

Primärer Abschluss (Geschätzt)

1. Februar 2030

Studienabschluss (Geschätzt)

1. Februar 2030

Studienanmeldedaten

Zuerst eingereicht

16. Januar 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

18. Februar 2025

Zuerst gepostet (Tatsächlich)

21. Februar 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 2023-503326-39-00
  • 2023/3729 (Andere Kennung: CSET number (Gustave Roussy ID))
  • 2023 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren